Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.77 |
| ▸ | EGLN2 | Q96KS0 | 12/20 | 0.77 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522924 | 1.00 | EGLN1 (0.77) | EGLN1EGLN2BBOX1FTO | |
| SCHEMBL522835 | 0.92 | EGLN1 (0.66) | EGLN1EGLN2BBOX1FTO | |
| SCHEMBL522832 | 0.91 | EGLN1 (0.64) | EGLN1EGLN2 | |
| SCHEMBL522734 | 0.88 | EGLN1 (0.61) | EGLN1EGLN2BBOX1FTO | |
| SCHEMBL15268851 | 0.87 | EGLN2 (1.00) | EGLN1EGLN2 | |
| SCHEMBL3914726 | 0.86 | EGLN1 (0.59) | EGLN1EGLN2BBOX1FTO | |
| SCHEMBL15268873 | 0.86 | EGLN2 (1.00) | EGLN1EGLN2 | |
| SCHEMBL15270936 | 0.84 | EGLN2 (1.00) | EGLN1EGLN2 | |
| SCHEMBL523101 | 0.83 | EGLN2 (0.71) | EGLN1EGLN2FTO | |
| SCHEMBL523031 | 0.83 | EGLN1 (0.55) | EGLN1EGLN2BBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4142721-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | Bioage Labs, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | EGLN1 24/4885EGLN2 9/4885BBOX1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.